Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
All news
Biotechnology
Privately-held Singapore-based company Tessa Therapeutics’ CD30-directed autologous CAR-T therapy has received US Food and Drug Administration (FDA) regenerative medicine advanced therapy (RMAT) designation. 17 March 2020
Biotechnology
US biotech Microbiotix has been awarded up to $2.86 million in non-dilutive funding by CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) to develop a new oral antibiotic to treat multidrug-resistant gonorrhea. 17 March 2020
Biotechnology
US clinical-stage biotech Provention Bio yesterday announced a temporary pause in the randomization of patients with newly diagnosed type 1 diabetes (T1D) into its global Phase III PROTECT study of PRV-031 (teplizumab. 17 March 2020
Biotechnology
Nucala (mepolizumab) has now been approved in Canada as an add-on maintenance treatment for use in adults, adolescents and children (aged six years and older) with severe eosinophilic asthma. 17 March 2020
Biotechnology
Californian company AcelRx Pharmaceuticals has announced a deal to buy privately-held US biopharma Tetraphase Pharmaceuticals. 16 March 2020
Biotechnology
The Franco-American pairing of Sanofi and Regeneron have rapidly ramped up a coronavirus (COVID-19) trial of Kevzara (sarilumab), a drug that is currently approved for rheumatoid arthritis (RA). 16 March 2020
Biotechnology
US drugmakers Eli Lilly and Incyte Corp have announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to baricitinib for the treatment of alopecia areata (AA). 16 March 2020
Biotechnology
A new partnership between Vancouver-based AbCellera and Eli Lilly will use antibodies from former COVID-19 patients as the basis for an antibody therapy for the disease. 16 March 2020
Biotechnology
Germany’s Merck and Pfizer today announced a disappointing update from the Phase III JAVELIN head and neck 100 study evaluating avelumab in addition to chemoradiotherapy (CRT) versus standard-of-care CRT in patients with untreated locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). 16 March 2020
Biotechnology
Oxford BioDynamics, a UK biotech focused on the discovery and development of biomarkers, based on regulatory 3D genome architecture, using its liquid biopsy platform EpiSwitch, announces that Dr Jon Burrows has been appointed as group chief executive, effective 23 March 2020. 16 March 2020
Biotechnology
German newspaper Welt am Sonntag over the weekend said that US President Donald Trump “had offered funds” to entice German mRNA-based drug specialist CureVac to move its recently started COVID-19 R&D work to the USA, and the German government was now “making counter-offers to tempt it to stay.” 16 March 2020
Biotechnology
Germany immunotherapeutics firm BioNTech today provided further details on its R&D effort, “Project Lightspeed,” to develop a potential vaccine to induce immunity and prevent COVID-19 infection in response to the growing global health threat posed by the disease. 16 March 2020
Biotechnology
Stockholm-based biotech Medivir has agreed a licensing deal for one of its pre-clinical research programs, with US biotech Tango Therapeutics. 16 March 2020
Biotechnology
The US Institute for Clinical and Economic Review (ICER) has released an Evidence Report assessing the comparative clinical effectiveness and value of treatments for sickle cell disease. 13 March 2020
Biotechnology
Janssen, a subsidiary of US healthcare giant Johnson & Johnson, today announced a collaboration with the Beth Israel Deaconess Medical Center (BIDMC) to support the development of a preventive vaccine candidate for COVID-19. 13 March 2020
Biotechnology
A bolstering of hopes that Spanish drugmaker PharmaMar (MSE: PHM) might have an answer for the COVID-19 coronavirus sent the company’s share price spiralling upwards on Friday. 13 March 2020
Biotechnology
US biotech major Gilead Sciences’ recent $4.9 billion buyout of Forty Seven put a spotlight on the latter’s star asset magrolimab, an anti-CD47 monoclonal antibody (MAb), as well as the target CD47, a protein on cancer cells sending out “don’t eat me” signal to avoid phagocytosis by microphages. 13 March 2020
Biotechnology
Chinese small-molecule drug discovery and development company Tyligand Bioscience has signed collaboration agreements with privately-held US company Context Therapeutics for the development, manufacturing, registration and future commercialization of onapristone extended release (ER). 13 March 2020
Biotechnology
In the USA, approximately 300,000 infants are born with sickle cell disease (SCD) each year.1 In this article, Dr Nicola Davies discusses how SCD is treated and what solutions are on the horizon. 13 March 2020
Biotechnology
While most Japanese pharma companies were shedding capital value by as much as 7% today, Mitsubishi Chemical closed up 3.48% at 625 yen on the news that one of its units had developed a vaccine against the novel coronavirus. 13 March 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze